Antibodies are among the most widely used tools in life science research, supporting applications ranging from western blotting and flow cytometry to immunohistochemistry and immunofluorescence. However, even a carefully designed experiment can be compromised if the antibody used has not been adequately validated.
Antibody validation helps confirm that an antibody specifically recognises its intended target and performs reliably in the intended application. Since validation methods and the amount of supporting data can differ considerably between antibodies, understanding how antibodies are assessed can help researchers make more informed choices and avoid unnecessary experimental setbacks.
Reliable antibody performance is essential for generating meaningful and reproducible scientific data. Ideally, an antibody should recognise its intended target while showing minimal interaction with unrelated proteins.
Non-specific binding or cross-reactivity can introduce background signals, unexpected staining or additional bands, making experimental results more difficult to interpret.
For this reason, modern antibody validation increasingly combines several complementary approaches rather than relying on a single method to demonstrate specificity and performance.
A fundamental question in antibody validation is simple: Does the antibody specifically recognise the intended target?
Establishing specificity can be challenging because related proteins, isoforms or proteins with similar epitopes may potentially produce unintended interactions.
Large-scale screening technologies can provide additional information by evaluating antibody binding against many different proteins. This makes it possible to identify potential cross-reactivity that might remain undetected with conventional single-target testing.
The objective is therefore not only to demonstrate that an antibody binds its intended protein, but also to assess whether unintended binding occurs under relevant experimental conditions.
Human proteome microarrays allow antibodies to be screened against thousands of recombinant proteins simultaneously.
This broad approach can help identify potential off-target interactions and provides additional evidence about antibody specificity beyond testing against the intended target alone.
Comprehensive specificity testing can be particularly valuable in sensitive applications such as flow cytometry, immunofluorescence and biomarker research, where unintended binding may influence data interpretation.
Specific target recognition does not necessarily mean that an antibody will perform equally well in every experimental method.
Proteins can be presented very differently depending on the application. Western blotting generally involves denatured and size-separated proteins, while immunohistochemistry requires recognition of proteins within preserved tissue structures. Flow cytometry may rely on detecting proteins in their native cellular environment.
Validation data should therefore always be considered in relation to the intended application.
Western blotting is widely used to evaluate antibody performance. A well-performing antibody should detect its intended target at the expected molecular weight while producing minimal non-specific bands.
Clear and reproducible banding patterns can provide valuable evidence that an antibody reliably detects the intended protein within a complex sample.
Specificity is particularly important in flow cytometry, where non-specific binding may interfere with the identification and analysis of individual cell populations.
Validation can demonstrate whether an antibody reliably distinguishes target-positive populations while maintaining sufficiently low background staining.
Immunohistochemistry (IHC) and immunofluorescence (IF) enable researchers to visualise proteins within cells and tissues while maintaining spatial information.
Validation in these applications considers whether the observed staining pattern corresponds to the expected biological distribution of the target. This helps distinguish genuine target localisation from potential non-specific antibody binding.
Tissue microarrays (TMAs) allow antibody staining patterns to be evaluated across multiple tissue samples on a single slide.
By comparing expected positive and negative tissues, researchers can identify unexpected staining patterns and potential cross-reactivity. TMAs can also provide useful information about antibody sensitivity across different levels of target expression.
This makes tissue microarrays a valuable component of comprehensive antibody validation strategies.
Reliable results depend not only on the initial validation of an antibody but also on consistent performance over time.
Quality-control approaches such as antibody sequence verification can help support consistency between production lots and reduce the risk of variability during long-term research projects.
This can be particularly relevant for researchers working on multi-year studies or experiments involving large numbers of samples.
No single validation method can answer every question about antibody performance. Instead, different techniques provide complementary information about specificity, sensitivity and suitability for particular research applications.
Considering proteome-wide specificity data, application-specific testing, tissue validation and appropriate quality-control measures can help researchers make more informed antibody selections, reduce experimental uncertainty and improve reproducibility.
Explore our selection of primary and secondary antibodies from leading suppliers. From highly validated primary antibodies to advanced secondary antibodies and conjugates, our portfolio helps you find the right solution for your research.
With the SZABO-SCANDIC Antibody Promise, you can choose the right antibodies for your research with added confidence.
Discover highly validated primary antibodies developed with a focus on specificity, sensitivity and reproducibility.
Save 10% on NeoBiotechnologies antibodies until December 31, 2026.
Discover primary and secondary antibodies supported by end-to-end control of antibody production.
Save 20% on Bethyl antibodies until December 31, 2026.
Explore high-quality secondary antibodies, conjugates and antibody fragments for advanced detection.
This article is based in part on the NeoBiotechnologies guide to antibody validation methods .
Sikorski, K., Mehta, A., Inngjerdingen, M. et al. A high-throughput pipeline for validation of antibodies. Nature Methods 15, 909-912 (2018). View publication
Uhlen, M., Bandrowski, A., Carr, S. et al. A proposal for validation of antibodies. Nature Methods 13, 823-827 (2016). View publication